Compare CRSR & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSR | ALMR |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2020 | 2026 |
| Metric | CRSR | ALMR |
|---|---|---|
| Price | $8.83 | $26.32 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 4.3M | 243.4K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.37 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $1,472,480,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.90 | N/A |
| P/E Ratio | $78.73 | ★ N/A |
| Revenue Growth | ★ 11.86 | N/A |
| 52 Week Low | $4.48 | $21.58 |
| 52 Week High | $13.10 | $24.58 |
| Indicator | CRSR | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 51.10 | N/A |
| Support Level | $8.18 | N/A |
| Resistance Level | $13.10 | N/A |
| Average True Range (ATR) | 0.55 | 0.00 |
| MACD | -0.13 | 0.00 |
| Stochastic Oscillator | 44.51 | 0.00 |
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the United States (U.S.), Americas (excluding U.S.) , Europe and the Middle East, and the Asia Pacific, of which maximum revenue is generated from United States (U.S.).
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.